Allergan will close the purchase of Valeant shortly. This transaction, valued at 13.000 billion dollars, receives advice from JP Morgan. The biotechnology sector is one of the most active in corporate transactions on Nasdaq and companies are positioning themselves to take the lierazgo market, which pursues Harbor with this last operation happens to those experienced in recent months between biotech .
negocios (dot) com//noticias/albergan-puja-valliant-08062016-2010
Who cares - if someone is getting the rights to keep all profits from Valeant products sold in LatAm for the next 20+ years, I can promise you they will be paying much more than $1B for those rights.
anyone seeing this?
Next quarter the $6.60 will become $5.50, then $4.75, then $3.75 until the chapter 11 restructuring is announced due to debt loads
They need to start selling assets immediately or issue a secondary share offering or bankruptcy will be imminent
Valeant will be sharing SIX abstracts on products in development with them. And you people think that this stock isn't going higher? And shorty, if it such a black sheep of the pharma industry, how come they got invited to ASCO in the first place?
see you at $31 by close.
-Papa/Pearson 1-2 punch
-Ackman on the board
-Senate Committee gone
-10-K filed on time and nothing material adverse contained within it
-10-Q coming this week
-Companies are starting to competitively bid for VRX assets
Things are ONLY going to get BETTER for shareholders from here. Ackman would have walked away if it were not the case. Sit tight and enjoy the ride higher folks.
If the smartest people in pharma were willing to acquire the company at north of $60, what does that tell you about the true worth of the company?